SDN-037 的新兴药物洞察与市场预测：2032

SDN-037是一种新型长效（每日两次）眼科类固醇製剂，经美国FDA核准用于治疗白内障手术后的眼部疼痛和发炎。目前可用的类固醇眼药水必须每 4 至 6 小时给药一次。除了给药方便之外，与市售製剂相比，SPARC的製剂是透明的，给药后呈乳状且视力模糊。

未来几年，由于广泛的研究和全球医疗保健支出的增加，急性眼痛市场格局将会改变。两家公司正在开发专注于治疗/改善疾病状况、评估挑战并探索可能影响 SDN-037 优势的机会的新方法的疗法。其他治疗急性眼痛的新兴产品预计将为SDN-037提供激烈的市场竞争，并且在不久的将来仿製药新兴疗法的推出预计将对市场产生重大影响。

本报告调查了八个主要国家的SDN-037市场，并提供了市场概况以及2024年至2032年的销售预测数据、竞争格局和国家趋势。

目录

第一章 报告简介

第2章 SDN-037治疗急性眼痛概述

• 产品详情
• 临床开发
  • 临床研究
  • 临床试验资讯
  • 安全性和有效性
• 其他开发活动
• 产品概要

第三章 竞争格局（上市治疗）

第四章竞争格局（后期新兴疗法）

第五章 SDN-037市场评估

• SDN-037治疗急性眼痛的市场前景
• 8个主要国家市场分析
  • SDN-037治疗急性眼痛在8个主要市场的市场规模
• 国家市场分析
  • 美国
  • 德国
  • 英国
  • 加拿大
  • 韩国

第6章SWOT分析

第七章 分析师观点

第8章附录

第九章 DelveInsight服务内容

第10章 免责声明

第 11 章关于 DelveInsight

第 12 章 报告购买选项

“"SDN-037 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SDN-037 for acute ocular pain (AOP) in the eight major markets. A detailed picture of the SDN-037 for acute ocular pain in the 8MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the SDN-037 for acute ocular pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SDN-037 market forecast analysis for acute ocular pain in the 8MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute ocular pain.

Drug Summary:

SDN-037 is a novel long-acting (twice-a-day) formulation of a US FDA-approved ophthalmic steroid for eye pain and inflammation after cataract surgery. Currently marketed steroidal eye drops requires administration every 4-6 h. Apart from providing dosing convenience, SPARC's formulation is clear compared to a marketed formulation which is milky, resulting in blurring of vision after administration.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SDN-037 description, mechanism of action, dosage and administration, research and development activities in acute ocular pain.
• Elaborated details on SDN-037 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SDN-037 research and development activities in acute ocular pain across the United States, Europe, Canada and South Korea.
• The report also covers the patents information with expiry timeline around SDN-037.
• The report contains forecasted sales of SDN-037 for acute ocular pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute ocular pain.
• The report also features the SWOT analysis with analyst views for SDN-037 in acute ocular pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SDN-037 Analytical Perspective by DelveInsight

In-depth SDN-037 Market Assessment

This report provides a detailed market assessment of SDN-037 for acute ocular pain in the eight major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada and South Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

SDN-037 Clinical Assessment

The report provides the clinical trials information of SDN-037 for acute ocular pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute ocular pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SDN-037 dominance.
• Other emerging products for acute ocular pain are expected to give tough market competition to SDN-037 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SDN-037 in acute ocular pain.
• Our in-depth analysis of the forecasted sales data of SDN-037 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SDN-037 in acute ocular pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of SDN-037?
• What is the clinical trial status of the study related to SDN-037 in acute ocular pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SDN-037 development?
• What are the key designations that have been granted to SDN-037 for acute ocular pain?
• What is the forecasted market scenario of SDN-037 for acute ocular pain?
• What are the forecasted sales of SDN-037 in the eight major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, Canada and South Korea?
• What are the other emerging products available and how are these giving competition to SDN-037 for acute ocular pain?
• Which are the late-stage emerging therapies under development for the treatment of acute ocular pain?

Table of Contents

1. Report Introduction

2. SDN-037 Overview in Acute ocular pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SDN-037 Market Assessment

• 5.1. Market Outlook of SDN-037 in Acute ocular pain
• 5.2. 8MM Analysis
  • 5.2.1. Market Size of SDN-037 in the 8MM for Acute ocular pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SDN-037 in the United States for Acute ocular pain
  • 5.3.2. Market Size of SDN-037 in Germany for Acute ocular pain
  • 5.3.3. Market Size of SDN-037 in France for Acute ocular pain
  • 5.3.4. Market Size of SDN-037 in Italy for Acute ocular pain
  • 5.3.5. Market Size of SDN-037 in Spain for Acute ocular pain
  • 5.3.6. Market Size of SDN-037 in the United Kingdom for Acute ocular pain
  • 5.3.7. Market Size of SDN-037 in Canada for Acute ocular pain
  • 5.3.8. Market Size of SDN-037 in South Korea for Acute ocular pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: SDN-037, Clinical Trial Description, 2023
• Table 2: SDN-037, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: SDN-037 Market Size in the 8MM, in USD million (2019-2032)
• Table 6: SDN-037 Market Size in the US, in USD million (2019-2032)
• Table 7: SDN-037 Market Size in Germany, in USD million (2019-2032)
• Table 8: SDN-037 Market Size in France, in USD million (2019-2032)
• Table 9: SDN-037 Market Size in Italy, in USD million (2019-2032)
• Table 10: SDN-037 Market Size in Spain, in USD million (2019-2032)
• Table 11: SDN-037 Market Size in the UK, in USD million (2019-2032)
• Table 12: SDN-037 Market Size in Canada, in USD million (2019-2032)
• Table 13: SDN-037 Market Size in South Korea, in USD million (2019-2032)

List of Figures

• Figure 1: SDN-037 Market Size in the 8MM, USD million (2019-2032)
• Figure 2: SDN-037 Market Size in the United States, USD million (2019-2032)
• Figure 3: SDN-037 Market Size in Germany, USD million (2019-2032)
• Figure 4: SDN-037 Market Size in France, USD million (2019-2032)
• Figure 5: SDN-037 Market Size in Italy, USD million (2019-2032)
• Figure 6: SDN-037 Market Size in Spain, USD million (2019-2032)
• Figure 7: SDN-037 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: SDN-037 Market Size in Canada, USD million (2019-2032)
• Figure 9: SDN-037 Market Size in South Korea, USD million (2019-2032)